PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
|Videos|June 8, 2011
Dr. Infante on the Future of BRAF Inhibitors in Melanoma
Author(s)Jeffrey R. Infante, MD
Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma
Advertisement
Jeffrey Infante, MD from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma
Advertisement
Related to this article
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss evolving evidence-based decision-making across CSCC.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5